Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir-Reference-Cited by-同舟云学术

Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir

Published:2021-03-01 Issue:3 Volume:37 Page:204-206
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Calza Leonardo¹,Borderi Marco¹,Colangeli Vincenzo¹,Testi Diletta¹,Amedeo Alberto¹,Bon Isabella²,Re Maria Carla²,Viale Pierluigi¹

Affiliation:

1. Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, “Alma Mater Studiorum” University of Bologna, Bologna, Italy.

2. Unit of Microbiology, S. Orsola Hospital, “Alma Mater Studiorum” University of Bologna, Bologna, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2020.0117

Reference11 articles.

1. Weight gain and integrase inhibitors

2. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens

3. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy

4. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV

5. Weight gain in people living with HIV switched to dual therapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial;Open Forum Infectious Diseases;2023-04-01

2. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081;JAIDS Journal of Acquired Immune Deficiency Syndromes;2022-12-01

3. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium;HIV Medicine;2022-08-08

4. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy;Infection;2021-08-27

5. HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review;Infectious Diseases and Therapy;2021-08-24